Search

PureTech Health Plc

Fermé

132.8 -0.75

Résumé

Variation du prix de l'action

24h

Actuel

Min

130.8

Max

135.4

Chiffres clés

By Trading Economics

Revenu

-114M

-45M

Ventes

-2.2M

1.9M

P/E

Moyenne du Secteur

10.369

36.442

BPA

-0.19

Marge bénéficiaire

-2,409.778

Employés

56

EBITDA

-148M

-46M

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

15M

328M

Ouverture précédente

133.55

Clôture précédente

132.8

PureTech Health Plc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 oct. 2025, 23:55 UTC

Actions en Tendance

Stocks to Watch: DraftKings, Texas Instruments, Intuitive Surgical, Pegasystems

21 oct. 2025, 23:49 UTC

Résultats

Texas Instruments Warns of Slower Semiconductor Industry Recovery -- Update

21 oct. 2025, 21:40 UTC

Résultats

Waste Connections 3Q Revenue Rises

21 oct. 2025, 21:14 UTC

Résultats
Principaux Mouvements du Marché

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth -- Update

21 oct. 2025, 21:05 UTC

Acquisitions, Fusions, Rachats

GE Vernova to Acquire Full Stake in Prolec GE Joint Venture

21 oct. 2025, 20:57 UTC

Acquisitions, Fusions, Rachats

DraftKings to Launch Prediction Markets Platform

21 oct. 2025, 20:38 UTC

Résultats

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth

21 oct. 2025, 20:35 UTC

Résultats

Capital One 3Q Sales, Profit Jump

21 oct. 2025, 20:32 UTC

Résultats

Texas Instruments 3Q Revenue Up on Growth Across End Markets

21 oct. 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 oct. 2025, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Hopes for Takaichi's Econ Steps -- Market Talk

21 oct. 2025, 23:39 UTC

Market Talk

Gold Consolidates; May Undergo Further Technical Correction -- Market Talk

21 oct. 2025, 23:36 UTC

Market Talk

BHP Has Hidden Leverage to Gold's Rush -- Market Talk

21 oct. 2025, 22:55 UTC

Acquisitions, Fusions, Rachats

Scentre Says This Forms Part of Capital Management Strategy

21 oct. 2025, 22:55 UTC

Acquisitions, Fusions, Rachats

Scentre: Continues to Evaluate Strategic Opportunities Including New JV Partners

21 oct. 2025, 22:54 UTC

Acquisitions, Fusions, Rachats

Scentre Notes Media Report on Possible Sale of Stake in Westfield Chermside to Dexus Fund

21 oct. 2025, 21:09 UTC

Market Talk
Résultats

Netflix Creators Have Started Using AI in Production -- Market Talk

21 oct. 2025, 20:58 UTC

Market Talk
Résultats

Netflix Aims to Build on 'KPop Demon Hunters' Mania -- Market Talk

21 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 oct. 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Financial Services Roundup: Market Talk

21 oct. 2025, 20:43 UTC

Résultats

Netflix Stock Drops After Earnings Miss Estimates -- Barrons.com

21 oct. 2025, 20:41 UTC

Résultats

Dow Industrials Hit Record, Boosted by Strong Earnings -- WSJ

21 oct. 2025, 20:33 UTC

Acquisitions, Fusions, Rachats

GE Vernova: Deal Accelerates Growth for Electrification Segment >GEV

21 oct. 2025, 20:33 UTC

Acquisitions, Fusions, Rachats

GE Vernova Acquiring Remaining 50% Stake of JV From Xignux >GEV

21 oct. 2025, 20:32 UTC

Acquisitions, Fusions, Rachats

GE Vernova: Prolec GE Expects Low Double-Digit Rev Growth in Coming Years >GEV

21 oct. 2025, 20:32 UTC

Acquisitions, Fusions, Rachats

GE Vernova: Prolec GE Expects $3B in Rev at 25% Adj EBITDA Margin in 2025 >GEV

21 oct. 2025, 20:32 UTC

Acquisitions, Fusions, Rachats

GE Vernova: $5.275B Purchase Price at Closing, Expected to Be Funded Equally With Cash & Debt >GEV

21 oct. 2025, 20:32 UTC

Acquisitions, Fusions, Rachats

GE Vernova Will Acquire Remaining 50% Stake of Prolec GE >GEV

21 oct. 2025, 20:31 UTC

Acquisitions, Fusions, Rachats

GE Vernova To Fully Acquire Prolec GE Joint Venture >GEV

21 oct. 2025, 20:29 UTC

Résultats

Northrop Stock Tumbles on Sales Disappointment. When Good Isn't Good Enough. -- Barrons.com

PureTech Health Plc prévision

Note du Consensus

By TipRanks

0 ratings

0

Achat

0

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos PureTech Health Plc

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
help-icon Live chat